{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:21:35Z","timestamp":1791955295136,"version":"4.3.4"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,5,15]]},"DOI":"10.2169\/internalmedicine.1172-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:37:59Z","timestamp":1548974279000},"page":"1405-1410","source":"Crossref","is-referenced-by-count":5,"title":["A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102"],"prefix":"10.2169","volume":"58","author":[{"given":"Takashi","family":"Yokoi","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Japan"},{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Police Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[{"name":"Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Koba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Police Hospital, Japan"},{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaro","family":"Torii","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Niki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Morimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Komuta","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Police Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan"},{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007."},{"key":"2","unstructured":"2. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996."},{"key":"3","unstructured":"3. Okamoto I, Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 10: 290-294, 2009."},{"key":"4","unstructured":"4. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer: results of a west Japanoncology group study. J Clin Oncol 28: 5240-5246, 2010."},{"key":"5","unstructured":"5. Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan OncologyGroup LETS study. Ann Oncol 24: 1326-1331, 2013."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shiroyama T, Kijima T, Komuta K, et al. Phase II tailored S-1regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol 70: 783-789, 2012.","DOI":"10.1007\/s00280-012-1958-z"},{"key":"7","unstructured":"7. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13: 247-255, 2012."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suzuki S, Karayama M, Inui N, et al. Continuation maintenance therapy with S-1 in chemotherapy-na\u00efve patients with advanced squamous cell lung cancer. Invest New Drugs 34: 490-496, 2016.","DOI":"10.1007\/s10637-016-0365-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tamura K, Okamoto I, Ozaki T, et al. Phase I\/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer 45: 2132-2137, 2009.","DOI":"10.1016\/j.ejca.2009.04.003"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Urata Y, Okamoto I, Takeda M, et al. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1and bevacizumab for chemotherapy-naive patients with advanced nonsquamous-small cell lung cancer. Cancer 119: 2275-2281, 2013.","DOI":"10.1002\/cncr.28048"},{"key":"11","unstructured":"11. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous-small-cell lung cancer. J Clin Oncol 31: 4349-4357, 2013."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/10\/58_1172-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T03:37:34Z","timestamp":1558150654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/10\/58_1172-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1172-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}